Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia

Surfactant Physiology and Pathogenesis of RDS

Respiratory Distress Syndrome (RDS), historically designated hyaline membrane disease, is the primary respiratory morbidity affecting preterm infants. The condition is driven by developmental deficiency in both the quantity and biochemical composition of pulmonary surfactant.

Biochemical Composition of Pulmonary Surfactant

Surfactant is an amphiphilic lipoprotein complex produced by type II alveolar pneumocytes:

• Phospholipids (80%): Predominantly dipalmitoylphosphatidylcholine (DPPC), also termed disaturated phosphatidylcholine. DPPC molecules arrange themselves at the air-liquid interface with their hydrophobic fatty acid tails projecting into the alveolar gas and hydrophilic head groups submerged in the hypophase, displacing water molecules.
• Neutral Lipids (10%): Mainly unesterified cholesterol, which modulates the fluidity and lateral mobility of the lipid monolayer.
• Surfactant Proteins (10%):
  • SP-B and SP-C (Hydrophobic Proteins): Essential for biophysical function. They facilitate the rapid insertion, spreading, and reorganization of DPPC into a tightly packed surface monolayer during expiration, lowering alveolar surface tension to near 0 mN/m. Congenital SP-B deficiency is an autosomal recessive, lethal condition causing intractable neonatal respiratory failure.
  • SP-A and SP-D (Hydrophilic Collectins): Mediate innate pulmonary host defense by binding bacterial, fungal, and viral pathogens, facilitating phagocytosis by alveolar macrophages. They do not lower surface tension directly.

Development and Regulation

Type II pneumocytes synthesize surfactant components within the endoplasmic reticulum and Golgi apparatus, packaging them into specialized storage organelles termed lamellar bodies. Surfactant synthesis begins around 20 to 24 weeks gestation, but functional biochemical maturity and extensive exocytosis into the alveolar space surge markedly after 32 to 34 weeks gestation, driven by fetal cortisol, thyroid hormones, and mechanical stretch.

Laplace's Law and Alveolar Instability

The biophysical behavior of the alveolus is governed by Laplace's Law for spherical structures:

$P = \frac{2T}{r}$

Where $P$ is the inward collapsing pressure, $T$ is the surface tension at the liquid-gas interface, and $r$ is the alveolar radius.

• In the healthy, surfactant-replete lung, surfactant molecules concentrate tightly as alveolar radius shrinks during expiration, reducing surface tension ($T$) toward zero. This preserves alveolar stability and prevents collapse even at low lung volumes.
• In surfactant deficiency, surface tension remains constantly high (~70 mN/m). As a consequence, smaller alveoli generate markedly higher collapsing pressures than adjacent larger alveoli, emptying their gas contents into larger units. This produces widespread microatelectasis, loss of functional residual capacity (FRC), intrapulmonary right-to-left shunting, severe ventilation-perfusion ($V/Q$) mismatch, and profound hypoxemia.
• Low lung compliance ($C = \Delta V / \Delta P$) sharply elevates the work of breathing, leading to diaphragmatic fatigue and hypercapnic respiratory failure.

Surfactant Deficiency (Prematurity)
               |
High Alveolar Surface Tension (Laplace's Law)
               |
Widespread Microatelectasis & Decreased FRC
               |
Ventilation-Perfusion Mismatch & Hypoxemia
               |
Capillary Shear Stress & Endothelial Injury
               |
Exudation of Proteinaceous Fibrin Fluid
               |
Hyaline Membrane Formation & Surfactant Inactivation

---

Clinical Manifestations and Diagnostic Radiography of RDS

Clinical signs of RDS typically appear immediately at birth or emerge within the first 4 to 6 hours of extrauterine life, progressively deteriorating over the subsequent 48 hours if untreated.

Cardinal Clinical Signs

• Tachypnoea: Respiratory rate exceeding 60 breaths/min, representing a compensatory response to generate adequate minute ventilation in the presence of tiny tidal volumes.
• Expiratory Grunting: The hallmark sign of RDS. Grunting is produced by dynamic vocal cord adduction during expiration against a closed glottis. This generates intrinsic positive end-expiratory pressure (auto-PEEP), which splints terminal bronchioles open and preserves end-expiratory alveolar volume.
• Increased Work of Breathing: Prominent sternal, subcostal, and intercostal retractions. The highly compliant, cartilaginous chest wall of the preterm neonate collapses inward under the extreme negative intrathoracic pressures required to inflate stiff, non-compliant lungs.
• Nasal Flaring: Reflex dilation of the alae nasi reduces upper airway resistance by up to 30%.
• Cyanosis: Central cyanosis in room air, reflecting severe right-to-left intrapulmonary and intracardiac shunting.

Characteristic Chest Radiographic Findings

Chest radiography (CXR) confirms the diagnosis and differentiates RDS from transient tachypnoea of the newborn (TTN), meconium aspiration, and congenital diaphragmatic hernia:

1. Diffuse Reticulogranularity ("Ground-Glass" Appearance): Symmetric, fine punctate opacities distributed evenly across both lung fields, reflecting thousands of microatelectatic alveolar clusters interspersed with dilated alveolar ducts.
2. Prominent Air Bronchograms: Dark, branching, air-filled major bronchi standing out clearly against the surrounding radiodense, non-aerated lung parenchyma.
3. Hypoaeration (Low Lung Volumes): Bell-shaped thoracic contour with fewer than 8 posterior ribs visible above the dome of the right hemidiaphragm on an inspiratory film.
4. Progression to "White-Out": In severe, untreated cases, complete bilateral opacification obscures the cardiac margins and diaphragmatic domes.

---

Antenatal Corticosteroids (ACS)

Antenatal administration of maternal corticosteroids is the cornerstone preventive therapy for preterm lung disease, dramatically altering neonatal survival worldwide.

Indications and Regimens

• Target Population: Under the European RDS consensus, offer a course when birth is highly likely within 7 days, from potential viability to before 34 weeks, with active neonatal care planned. Later-preterm use, including planned caesarean birth without labour, requires individual obstetric assessment of respiratory benefit and neonatal hypoglycaemia risk.
• Standard Evidence-Based Regimens:
  • Betamethasone: 12 mg intramuscularly, two doses administered 24 hours apart.
  • Dexamethasone: 6 mg intramuscularly, four doses administered 12 hours apart.

Molecular Mechanism and Clinical Impact

Betamethasone and dexamethasone cross the placenta and promote structural and biochemical fetal lung maturation. Within fetal lungs, they bind intracellular glucocorticoid receptors in type II pneumocytes, stimulating transcription of surfactant proteins (SP-A, SP-B, SP-C) and enzymes in the CDP-choline phospholipid pathway. They also upregulate epithelial sodium channels (ENaC), accelerate alveolar septation, and thin the pulmonary interstitial mesenchyme.

---

Non-Invasive Respiratory Support vs. Invasive Mechanical Ventilation

The management paradigm for preterm infants has shifted decisively from routine delivery room intubation toward early, non-invasive respiratory stabilization.

Early Continuous Positive Airway Pressure (CPAP)

• The European Consensus Guidelines on RDS recommend that all spontaneously breathing preterm infants with respiratory distress should be started on nasal CPAP of 6 to 8 cmH2O immediately in the delivery room.
• CPAP recruits atelectatic alveoli, establishes and maintains functional residual capacity, prevents alveolar end-expiratory collapse, stabilizes the compliant thoracic cage, and conserves endogenous surfactant.
• Trials including COIN and SUPPORT support early CPAP as an alternative to routine intubation. SUPPORT found fewer days of mechanical ventilation, but no significant difference in its primary outcome of death or BPD. NeOProM combined trials of oxygen-saturation targets.
• Target Oxygenation: During the first minutes after birth, use the age-specific transitional saturation targets in the ERC algorithm. After transition, the European RDS target for oxygen-treated extremely preterm infants is 90–94%, with alarms at 89% and 95%. Titrate oxygen to limit both hypoxaemia and oxygen toxicity; do not impose the maintenance target immediately at birth.

---

Exogenous Surfactant Replacement Therapy

Exogenous surfactant instillation directly restores alveolar surface tension, improves lung compliance, expands functional residual capacity, and decreases intrapulmonary shunting within minutes of administration.

Surfactant Preparations

Natural animal-derived surfactants are significantly more effective than synthetic products lacking surfactant-associated proteins:

• Poractant Alfa (Porcine Lung Extract - Curosurf): Contains high concentrations of phospholipids and SP-B/SP-C. Administered at an initial dose of 200 mg/kg (2.5 mL/kg). Clinical trials demonstrate that this initial 200 mg/kg dose achieves more rapid oxygenation improvement and significantly lower mortality compared to 100 mg/kg initial doses of bovine preparations.
• Bovine Extracts: Beractant 100 mg/kg (4 mL/kg) and bovactant 50 mg/kg (1.2 mL/kg) have different recommended doses; do not interchange them.
• Further doses may be needed for persistent RDS after other causes of deterioration are excluded. Repeat dose, interval and maximum number depend on the preparation; follow its product information.

Surfactant Administration Thresholds

According to European Consensus Guidelines:

• Give surfactant for worsening RDS on non-invasive support. For infants >28 weeks, the 2025 European consensus suggests a threshold of FiO2 ≥0.30 on support at a mean airway pressure of ≥6 cmH2O, or lung-ultrasound evidence of surfactant need. In infants <28 weeks, consider selective prophylaxis within the first hour after stabilisation if early RDS signs are present.
• Surfactant should be administered early in the disease course (ideally within the first 2 hours of life), as delayed administration after significant epithelial injury has occurred yields inferior outcomes.

Administration Techniques

1. LISA / MIST (Less Invasive Surfactant Administration / Minimally Invasive Surfactant Therapy):
   • Technique: While the infant breathes spontaneously on continuous nasal CPAP, a thin, flexible catheter (e.g., 16–18G vascular catheter or dedicated fine feeding tube) is guided through the vocal cords into the trachea under direct or video laryngoscopy. Surfactant is slowly instilled over 1 to 3 minutes, and the catheter is withdrawn immediately.
   • Advantages: The infant maintains spontaneous diaphragmatic breathing throughout the procedure. It completely avoids positive pressure mechanical ventilation via an endotracheal tube, reducing barotrauma, volutrauma, and the need for mechanical ventilation within the first 72 hours, while decreasing the incidence of BPD.
2. INSURE (INtubate - SURfactant - Extubate):
   • The infant is intubated with an endotracheal tube, surfactant is delivered via bolus, the infant is stabilized with brief manual or mechanical ventilation, and then extubated directly back to CPAP within 15 to 30 minutes.
3. Endotracheal Bolus with Ongoing Mechanical Ventilation:
   • Reserved for infants who are apnoeic, hemodynamically unstable, or failing non-invasive CPAP despite surfactant administration.

---

Bronchopulmonary Dysplasia (BPD) / Chronic Lung Disease of Prematurity

Bronchopulmonary Dysplasia represents the most frequent long-term pulmonary complication of extreme prematurity.

"Old" vs. "New" BPD Pathophysiology

• Old BPD (Northway et al., 1967): Occurred in moderately preterm or term infants exposed to aggressive mechanical ventilation with high peak inspiratory pressures and prolonged hyperoxia. Characterized pathologically by severe airway injury, squamous metaplasia, marked peribronchial smooth muscle hypertrophy, alternating atelectasis and emphysematous bullae, and extensive parenchymal fibrosis.
• New BPD (Jobe, 1999): Occurs in extremely preterm infants (<28 weeks gestation, birth weight <1,000 g) whose lungs are in the canalicular or early saccular stages of development. The hallmark is arrest of alveolar septation and pulmonary microvascular development. Histology demonstrates simplified, enlarged alveoli with reduced total surface area for gas exchange, a deficient capillary network, and variable dysmorphic pulmonary arterial remodeling predisposing to pulmonary hypertension.

Diagnostic Criteria and Severity Classification

The classic 2001 NICHD definition requires supplemental oxygen for at least 28 cumulative days. For infants born before 32 weeks, assess severity at 36 weeks postmenstrual age (PMA) or discharge, whichever occurs first, using the table below. This oxygen-based framework differs from the 2019 Jensen definition, which grades respiratory support at 36 weeks irrespective of oxygen exposure; nasal flow >2 L/min is grade 2 and invasive ventilation is grade 3.

Evidence-Based Management and Prevention

• Lung-Protective Ventilation: Utilize volume-targeted ventilation (VTV) targeting tidal volumes of 4 to 6 mL/kg to prevent volutrauma, combined with permissive hypercapnia (target pH 7.22–7.35, PaCO2 50–65 mmHg / 6.5–8.5 kPa).
• Caffeine Citrate: Initiated within the first 72 hours of life (loading dose 20 mg/kg, maintenance 5–10 mg/kg/day). Caffeine stimulates respiratory drive and facilitates extubation. In the CAP trial, positive airway pressure was stopped a median one week earlier, and BPD was reduced; follow-up showed improved survival without neurodevelopmental disability at 18–21 months.
• Postnatal Corticosteroids: High-dose systemic dexamethasone causes neurotoxicity and significantly increases the incidence of cerebral palsy. Low-dose dexamethasone (e.g., DART protocol: cumulative dose 0.89 mg/kg over 10 days) is restricted strictly to ventilator-dependent infants after 1 to 2 weeks of life who cannot be weaned from mechanical ventilation and face a very high risk of developing fatal or severe BPD.
• Inhaled Therapies and Diuretics: Early inhaled budesonide reduced BPD in trials, but follow-up raised concern about increased mortality; routine prevention is not recommended. Routine bronchodilators and chronic diuretics have not demonstrated durable benefit and should not be used routinely.

---

Post-Discharge Respiratory Syncytial Virus (RSV) Immunoprophylaxis

Infants with bronchopulmonary dysplasia possess restricted airway calibers and abnormal pulmonary vascular architecture. Infection with Respiratory Syncytial Virus (RSV) precipitates severe bronchiolitis, respiratory failure, prolonged ICU admission, and death.

Prophylactic Regimens

• Palivizumab: A humanized IgG1 monoclonal antibody directed against the conserved antigenic site of the RSV fusion (F) glycoprotein, blocking viral cell entry and syncytium formation.
  • Dosing: 15 mg/kg intramuscularly administered every 30 days during the winter epidemic season (up to a maximum of 5 doses).
  • European Licensed Indications: Palivizumab is indicated for infants born at ≤35 weeks who are <6 months old at RSV-season onset; children <2 years needing BPD treatment within the previous 6 months; and children <2 years with haemodynamically significant congenital heart disease. National programmes determine clinical eligibility and choice of prophylaxis; the older AAP <29-week criterion is not a pan-European rule.
• Nirsevimab: A recombinant human IgG1κ monoclonal antibody targeting the prefusion conformation of the RSV F protein. Engineered with a triple-amino-acid substitution in the Fc region that prolongs its elimination half-life to ~60 to 70 days. A single intramuscular dose provides season-long protection (at least 5 months), significantly simplifying compliance and reducing RSV hospitalizations across Europe.